title: [Venous thrombosis and bowel perforation].
abstract: In cancer chemotherapy, serious complications including arterial and venous thrombosis and occlusion may occur, especially when bevacizumab(Bmab)is administered. Low-molecular weight heparin(LMWH)is recommended for the treatment of venous thrombosis in the guideline of Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer' by ASCO. Full-dose anticoagulation is reported to raise no risk of bleeding tendency. For a bowel perforation case, emergency operation may be required. In the treatment of such complications, wound healing delay due to Bmab administration has to be taken into account.
authors.affiliation: Department of Translational Oncology, Tokyo Medical and Dental Universty, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uetake
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D009369:Neoplasms / Q000188:drug therapy; D012307:Risk Factors; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab